Antibody-Proteolysis Targeting Chimera Conjugate Enables Selective Degradation of Receptor-Interacting Serine/Threonine-Protein Kinase 2 in HER2+ Cell Lines-Reference-Cited by-同舟云学术

Antibody-Proteolysis Targeting Chimera Conjugate Enables Selective Degradation of Receptor-Interacting Serine/Threonine-Protein Kinase 2 in HER2+ Cell Lines

Published:2023-11-02 Issue:11 Volume:34 Page:2049-2054
ISSN:1043-1802
Container-title:Bioconjugate Chemistry
language:en
Short-container-title:Bioconjugate Chem.

Author:

Chan Karina¹²,Sathyamurthi Preethi Soundarya¹,Queisser Markus A.¹^ORCID,Mullin Michael¹,Shrives Harry¹,Coe Diane M.¹,Burley Glenn A.²^ORCID

Affiliation:

1. GSK, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, United Kingdom

2. Department of Pure and Applied Chemistry, University of Strathclyde, Glasgow G1 1XL, United Kingdom

Funder

Engineering and Physical Sciences Research Council

University of Strathclyde

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Pharmaceutical Science,Pharmacology,Biomedical Engineering,Bioengineering,Biotechnology

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.bioconjchem.3c00366

Reference31 articles.

1. PROTAC targeted protein degraders: the past is prologue

2. Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders

3. Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation

4. Catalytic in vivo protein knockdown by small-molecule PROTACs

5. Homobivalent, Trivalent, and Covalent PROTACs: Emerging Strategies for Protein Degradation

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glutathione-dependent degradation of SMARCA2/4 for targeted lung cancer therapy with improved selectivity;European Journal of Medicinal Chemistry;2024-11

2. Collaborative GSK–University of Strathclyde doctoral research and training programmes: Transforming approaches to industry–academia engagement;Drug Discovery Today;2024-09

3. Single-Domain Antibodies as Antibody–Drug Conjugates: From Promise to Practice—A Systematic Review;Cancers;2024-07-27

4. Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions;Bioconjugate Chemistry;2024-07-11

5. New-generation advanced PROTACs as potential therapeutic agents in cancer therapy;Molecular Cancer;2024-05-21